Press Releases

Intercytex announces TrichoCyte distribution option with Bosley

Manchester, May 6th, 2004: Intercytex today announced it has entered into an agreement with Bosley Medical providing them with an option to negotiate distribution of its hair induction product - TrichoCyte. Bosley currently have 75 hair transplant clinics and consultation centres throughout the US, and have the potential to distribute TrichoCyte not only within their established clinics, but also to the hair transplant community in general.

Dr Paul Kemp, CEO and CSO of Intercytex, said “We are very pleased to be working with Bosley in this way - they undoubtedly have performed more surgical hair transplants than anyone else in the world and their experience of the market will be extremely important as we further develop TrichoCyte.” Commenting further on behalf of Bosley, President and CEO John R Ohanesian said “We are excited to have the opportunity to work with this leader in cellular biology and tissue engineering.”

Based on emerging positive results from its Phase I study, Intercytex also announced it is planning to initiate Phase II US and UK multi-centre clinical trials of TrichoCyte later this year.

Principal Investigator for the forthcoming trials will be Dr Jerry Cooley (Head of the Carolina Dermatology Hair Center) who said “Having spent the last three years working closely with Intercytex on clinical development of follicular cell implantation, it is extremely rewarding to see that TrichoCyte is progressing towards the next key stage of its product development.”

Several individuals have so far been treated with TrichoCyte as part of a UK-based safety study conducted under the guidance of Dr Bessam Farjo of the Farjo Clinic - none of the volunteers treated exhibited any evidence of adverse responses. Dr Farjo commented “I am delighted that TrichoCyte has proven safe in all volunteers enrolled into the trial, as this approach to new hair induction will represent a step-change in the way male pattern baldness is treated in the future.”

TrichoCyte comprises highly specialised inductive dermal papillae cells capable of mediating hair growth by formation of new follicular structures. The product will be indicated for treatment of male pattern baldness which currently affects over 40 million individuals in the US.

About Bosley:

Bosley enters its 30th year in surgical hair transplantation with more than 180,000 procedures performed on men and women from sixty different nations since 1974. Bosley advanced many of the artistic techniques used worldwide today to achieve natural results under the leadership of hair restoration pioneer and company founder L Lee Bosley, MD. Under the direction of Bosley's Medical Director, Ken Washenik, MD, PhD, Bosley practises state-of-the-art follicular unit hair transplantation.